Tissue Regenix Group PLC Notice of Results (8568F)
February 26 2018 - 2:01AM
UK Regulatory
TIDMTRX
RNS Number : 8568F
Tissue Regenix Group PLC
26 February 2018
Tissue Regenix Group plc
Notice of Results
Leeds, 26 February 2018 - Tissue Regenix Group (AIM:TRX)
("Tissue Regenix" or "The Group") the regenerative medical devices
company announces it will release its unaudited preliminary results
for the year ended 31 December 2017 on Monday 19 March.
Further information regarding an analyst call will follow in due
course.
For more Information:
Tissue Regenix Group plc Tel: 0330
Caitlin Pearson Head of Communications 430 3073
/ 07920272
441
---------------------------------------- ------------
Jefferies International Ltd Tel: 020
Simon Hardy / Christopher Binks 7029 8000
---------------------------------------- ------------
FTI Consulting Tel: 0203
Brett Pollard / Mo Noonan/ Rob Winder 727 1000
======================================== ============
About Tissue Regenix
Tissue Regenix is a leading medical devices company in the field
of regenerative medicine. Tissue Regenix was formed in 2006 when it
was spun-out from the University of Leeds, UK. The company's
patented decellularisation ('dCELL(R) ') technology removes DNA and
other cellular material from animal and human soft tissue leaving
an acellular tissue scaffold which is not rejected by the patient's
body and can then be used to repair diseased or worn out body
parts. Current applications address many critical clinical needs
such as sports medicine, heart valve replacement and wound
care.
In November 2012 Tissue Regenix Group plc set up a subsidiary
company in the United States - 'Tissue Regenix Wound Care Inc.',
January 2016 saw the establishment of joint venture GBM-V, a multi-
tissue bank based in Rostock, Germany.
In August 2017 Tissue Regenix acquired CellRight Technologies(R)
, a biotech company that specializes in regenerative medicine and
is dedicated to the development of innovative osteoinductive and
wound care scaffolds that enhance healing opportunities of defects
created by trauma and disease. CellRight's human osteobiologics may
be used in spine, trauma, general orthopedic, foot & ankle,
dental, and sports medicine surgical procedures.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NORDMGZZZKZGRZZ
(END) Dow Jones Newswires
February 26, 2018 02:01 ET (07:01 GMT)
Tissue Regenix (LSE:TRX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Tissue Regenix (LSE:TRX)
Historical Stock Chart
From Jul 2023 to Jul 2024